Elizabeth J Lilley1,2, John W Scott1,3, Joel E Goldberg3, Christy E Cauley4,5, Jennifer S Temel5, Andrew S Epstein6, Stuart R Lipsitz1, Brittany L Smalls7, Adil H Haider1,3, Angela M Bader1,8, Joel S Weissman1, Zara Cooper1,3,4. 1. Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, MA. 2. Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ. 3. Department of Surgery, Brigham and Women's Hospital, Boston, MA. 4. Ariadne Labs, Boston, MA. 5. Department of Surgery, Massachusetts General Hospital, Boston, MA. 6. Gastrointestinal Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY. 7. Center for Health Services Research, University of Kentucky College of Medicine, Lexington, KY. 8. Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA.
Abstract
OBJECTIVE: To compare survival, readmissions, and end-of-life care after palliative procedures compared with medical management for malignancy-associated bowel obstruction (MBO). BACKGROUND: MBO is a late complication of intra-abdominal malignancy for which surgeons are frequently consulted. Decisions about palliative treatments, which include medical management, surgery, or venting gastrostomy tube (VGT), are hampered by the paucity of outcomes data relevant to patients approaching the end of life. METHODS: Retrospective study using 2001 to 2012 Surveillance, Epidemiology, and End Results-Medicare data of patients 65 years or older with stage IV ovarian or pancreatic cancer who were hospitalized for MBO. Multivariate competing-risks regression models were used to compare the following outcomes: survival, readmission for MBO, hospice enrollment, intensive care unit (ICU) care in the last days of life, and location of death in an acute care hospital. RESULTS: Median survival after MBO admission was 76 days (interquartile range 26-319 days). Survival was shorter after VGT [38 days (interquartile range 23-69)] than medical management [72 days (23-312)] or surgery [128 days (42-483)]. As compared to medical management, patients treated with VGT had fewer readmissions [subdistribution hazard ratio 0.41 (0.29-0.58)], increased hospice enrollment [1.65 (1.42-1.91)], and less ICU care [0.69 (0.52-0.93)] and in-hospital death [0.47 (0.36-0.63)]. Surgery was associated with fewer readmissions [0.69 (0.59-0.80)], decreased hospice enrollment [0.84 (0.76-0.92)], and higher likelihood of ICU care [1.38 (1.17-1.64)]. CONCLUSIONS: VGT is associated with fewer readmissions and lower intensity healthcare utilization at the end of life than do medical management or surgery. Given the limited survival, regardless of management, hospitalization with MBO carries prognostic significance and presents a critical opportunity to identify patients' priorities for end-of-life care.
OBJECTIVE: To compare survival, readmissions, and end-of-life care after palliative procedures compared with medical management for malignancy-associated bowel obstruction (MBO). BACKGROUND: MBO is a late complication of intra-abdominal malignancy for which surgeons are frequently consulted. Decisions about palliative treatments, which include medical management, surgery, or venting gastrostomy tube (VGT), are hampered by the paucity of outcomes data relevant to patients approaching the end of life. METHODS: Retrospective study using 2001 to 2012 Surveillance, Epidemiology, and End Results-Medicare data of patients 65 years or older with stage IV ovarian or pancreatic cancer who were hospitalized for MBO. Multivariate competing-risks regression models were used to compare the following outcomes: survival, readmission for MBO, hospice enrollment, intensive care unit (ICU) care in the last days of life, and location of death in an acute care hospital. RESULTS: Median survival after MBO admission was 76 days (interquartile range 26-319 days). Survival was shorter after VGT [38 days (interquartile range 23-69)] than medical management [72 days (23-312)] or surgery [128 days (42-483)]. As compared to medical management, patients treated with VGT had fewer readmissions [subdistribution hazard ratio 0.41 (0.29-0.58)], increased hospice enrollment [1.65 (1.42-1.91)], and less ICU care [0.69 (0.52-0.93)] and in-hospital death [0.47 (0.36-0.63)]. Surgery was associated with fewer readmissions [0.69 (0.59-0.80)], decreased hospice enrollment [0.84 (0.76-0.92)], and higher likelihood of ICU care [1.38 (1.17-1.64)]. CONCLUSIONS: VGT is associated with fewer readmissions and lower intensity healthcare utilization at the end of life than do medical management or surgery. Given the limited survival, regardless of management, hospitalization with MBO carries prognostic significance and presents a critical opportunity to identify patients' priorities for end-of-life care.
Authors: Craig C Earle; Elyse R Park; Bonnie Lai; Jane C Weeks; John Z Ayanian; Susan Block Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544
Authors: Emily A Meier; Jarred V Gallegos; Lori P Montross Thomas; Colin A Depp; Scott A Irwin; Dilip V Jeste Journal: Am J Geriatr Psychiatry Date: 2016-01-22 Impact factor: 4.105
Authors: Stephen J Mooney; Megan Winner; Dawn L Hershman; Jason D Wright; Daniel L Feingold; John D Allendorf; Alfred I Neugut Journal: Gynecol Oncol Date: 2012-12-26 Impact factor: 5.482
Authors: Megan Winner; Stephen J Mooney; Dawn L Hershman; Daniel L Feingold; John D Allendorf; Jason D Wright; Alfred I Neugut Journal: JAMA Surg Date: 2013-08 Impact factor: 14.766
Authors: Jennifer W Mack; Angel Cronin; Nancy L Keating; Nathan Taback; Haiden A Huskamp; Jennifer L Malin; Craig C Earle; Jane C Weeks Journal: J Clin Oncol Date: 2012-11-13 Impact factor: 44.544
Authors: Harriet L Mather; Heather Coats; Kristen Desanto; J Nicholas Dionne-Odom; Cardinale B Smith; Laura P Gelfman Journal: J Palliat Med Date: 2019-04 Impact factor: 2.947
Authors: Sarah B Bateni; Richard J Bold; Frederick J Meyers; Daniel J Canter; Robert J Canter Journal: J Surg Oncol Date: 2017-10-16 Impact factor: 3.454
Authors: Rachel A Pozzar; Andrea C Enzinger; Hanneke Poort; Ann Furey; Heidi Donovan; Meghan Orechia; Embree Thompson; Anna Tavormina; Anny T H R Fenton; Tim Jaung; Ilana M Braun; Andrea DeMarsh; Mary E Cooley; Alexi A Wright Journal: J Palliat Med Date: 2022-03-17 Impact factor: 2.947
Authors: Paul R Duberstein; Michael Chen; Michael Hoerger; Ronald M Epstein; Laura M Perry; Sule Yilmaz; Fahad Saeed; Supriya G Mohile; Sally A Norton Journal: J Pain Symptom Manage Date: 2019-10-19 Impact factor: 3.612